GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » EBITDA Margin %

BIOA (Bioage Labs) EBITDA Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Bioage Labs EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bioage Labs's EBITDA for the three months ended in Dec. 2024 was $-20.76 Mil. Bioage Labs's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Bioage Labs's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.


Bioage Labs EBITDA Margin % Historical Data

The historical data trend for Bioage Labs's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioage Labs EBITDA Margin % Chart

Bioage Labs Annual Data
Trend Dec22 Dec23 Dec24
EBITDA Margin %
- - -

Bioage Labs Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Bioage Labs's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Bioage Labs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioage Labs's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bioage Labs's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Bioage Labs's EBITDA Margin % falls into.


;
;

Bioage Labs EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Bioage Labs's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-68.575/0
= %

Bioage Labs's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-20.763/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioage Labs  (NAS:BIOA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Bioage Labs EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Bioage Labs's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioage Labs Business Description

Traded in Other Exchanges
N/A
Address
1445A South 50th Street, Richmond, CA, USA, 94804
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

Bioage Labs Headlines

From GuruFocus